MOVANTIK: payments to doctors
Payments that named MOVANTIK as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1M
- Providers
- 12,659
- Transactions
- 39,278
- Average per transaction
- $26
The per-transaction average — $26 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 12,659 providers the average total is $80, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Redhill Biopharma Inc. | $740,619 | 72.9% |
| Valinor Pharma, LLC | $167,456 | 16.5% |
| AstraZeneca | $99,683 | 9.8% |
| Daiichi Sankyo Inc. | $7,458 | 0.7% |
| Astrazeneca AB | $1,125 | 0.1% |